Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia drug
Biotech
Neurocrine's KarXT rival hits in phase 2—but only at low dose
Neurocrine achieved its hoped-for profile in the schizophrenia trial but only saw efficacy at the lowest dose—the three higher doses all failed.
Nick Paul Taylor
Aug 28, 2024 7:53am
Karuna's schizophrenia drug clears blood pressure test
Nov 17, 2023 8:52am
Newron's schizophrenia data boost chances of historic approval
Feb 16, 2023 8:30am
Karuna hits goal in schizophrenia phase 3, teeing up 2023 filing
Aug 8, 2022 9:48am
Cerevel stock doubles on success of phase 1b schizophrenia trial
Jun 30, 2021 7:15am
Alkermes sees swift turnaround for rejected schizophrenia med
Dec 29, 2020 8:18am
